Verastem (VSTM) Registration Filing summary

Company overview and business model

• Focuses on developing and commercializing novel small molecule drugs targeting RAS/MAPK pathway-driven cancers, including ovarian, lung, and pancreatic cancers.

• Lead candidates avutometinib (RAF/MEK inhibitor) and defactinib (FAK inhibitor) are in late-stage clinical development, with regulatory submissions underway.

• Avutometinib and defactinib combination has received FDA breakthrough and orphan drug designations for low-grade serous ovarian cancer (LGSOC) and pancreatic cancer.

• NDA for avutometinib and defactinib in recurrent KRAS mutant LGSOC accepted by FDA with priority review and a June 30, 2025 action date.

• Plans to seek regulatory approval in additional global markets, including Europe and Japan.

Use of proceeds and capital allocation

• All shares offered are for resale by selling stockholders; no proceeds will be received by the company from these sales.

• Company will bear registration and listing expenses, while selling stockholders cover brokerage and related costs.

• Gross proceeds of approximately $7.5 million were raised in a private placement at $5.2931 per share on January 13, 2025.

• Selling stockholders have participation rights in future equity offerings up to $2.5 million for three years post-closing.

Risk factors and disclosures

• Investment involves risks that could adversely affect business, results, and stock value, including clinical, regulatory, and financial uncertainties.

• Forward-looking statements are subject to risks such as clinical trial outcomes, regulatory approvals, commercialization success, IP protection, and financing needs.

• Additional risks are detailed in the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent SEC filings.